In AYAs, the ASH guideline panel recommends pediatric-inspired (asparaginase-containing) regimens for treatment-naïve B-ALL and T-ALL, and blinatumomab for relapsed/refractory B-ALL.
Barriers to accessing emergency hormonal contraception guidelines contribute to “inconsistent provision and reduced adherence to evidence-based recommendations”, study reveals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results